CClinicalTrials.gg
Not yet recruitingNCT07835529Updated Sep 23, 2026

Magnesium Sulphate for Neonatal Asphyxia and Length of Hospital Stay

An interventional study of Magnesium sulphate and Supportive care and standard neonatal intensive care unit care in Duration of Hospitalization and Neonatal Mortality Rate, sponsored by Sargodha Medical College. Not yet recruiting. Open to participants aged Up to 24 Hours. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Sargodha Medical College · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
Up to 24 Hours
Sex
All
01

Study summary

Neonatal asphyxia causes significant global morbidity, frequently resulting in Hypoxic-Ischemic Encephalopathy (HIE). In resource-limited settings where therapeutic hypothermia is unavailable, affordable neuroprotective options are needed. Intravenous magnesium sulphate blocks NMDA receptors, limiting cellular calcium influx and neuroinflammation. This randomized controlled trial evaluates whether adjuvant intravenous magnesium sulphate (250\text{ mg/kg} within 6 hours of birth) reduces the duration of hospital stay and improves short-term clinical outcomes in term neonates with birth asphyxia.

Read the detailed description

Perinatal asphyxia triggers secondary brain injury through glutamate release, NMDA receptor overactivation, and intracellular calcium accumulation, leading to Hypoxic-Ischemic Encephalopathy (HIE). Magnesium sulphate acts as a neuroprotective agent by blocking NMDA-gated channels, stabilizing cell membranes, and reducing cerebral edema.

This prospective, randomized trial evaluates 72 term neonates (\ge 37 weeks) admitted with birth asphyxia within 24 hours of birth. Participants are allocated into two equal groups (n = 36 each):

Intervention Group: Receives standard NICU care plus IV Magnesium Sulphate (250\text{ mg/kg} over 30\text{--}60 minutes) within 6 hours of life.

Control Group: Receives standard NICU supportive care alone.

02

Conditions studied

  • Duration of Hospitalization
  • Neonatal Mortality Rate
03

Who can participate

Ages eligible
Up to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Term neonates (gestational age more than 37 weeks),
  2. age less than 24 hours,
  3. diagnosed with birth asphyxia (Apgar score less than 5 at 5 minutes or 4)Evidence of hypoxic-ischemic injury within 6 hours of birth).

Exclusion criteria

Exclusion Criteria:

  1. Major congenital anomalies
  2. neonatal sepsis at admission,
  3. preterm neonates (\<37 weeks),
  4. metabolic disorders.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Magnesium sulphate group

    Intravenous infusion of Magnesium Sulphate at a dose of 250\\text{ mg/kg} administered over 30\\text{--}60 minutes within 6 hours of birth

    Drug: Magnesium sulphate

  • Active comparator
    Control group

    Term neonates with birth asphyxia who receive standard NICU supportive management alone

    Other: Supportive care and standard neonatal intensive care unit care

Interventions

  • DrugMagnesium sulphate

    Intravenous infusion of Magnesium Sulphate at a dose of 250\\text{ mg/kg} administered over 30\\text{--}60 minutes within 6 hours of birth

  • OtherSupportive care and standard neonatal intensive care unit care

    Standard clinical supportive care including prompt resuscitation, maintenance of adequate ventilation, correction of metabolic abnormalities, and management of complications without Magnesium Sulphate.

05

What researchers measure

Primary outcomes

  1. Duration of Hospital Stay

    Total length of time the neonate requires inpatient care, measured as the number of days from admission to the Neonatal Intensive Care Unit (NICU) until formal hospital discharge.

    Time frame: Up to 6 months

Secondary outcomes

  1. Neonatal Mortality Rate

    Incidence of all-cause mortality during the hospitalization period (recorded as survived or died).

    Time frame: up to 6 months

  2. Seizure Status at Discharge

    Clinical assessment of seizure activity and control (categorized as controlled or uncontrolled).

    Time frame: Up to 6 months

  3. Time to Establish Oral Feeding

    Successful achievement of full oral/suck feeding without relying on tube feeding (categorized as suck feeding established or not established

    Time frame: up to 6 months

  4. Neurological Examination at Discharge

    Clinical evaluation of neurological recovery, specifically assessing muscle tone and primitive reflexes (categorized as normal or abnormal).

    Time frame: With in 1 week

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07835529
Lead sponsor
Sargodha Medical College
Responsible party
Sponsor
First posted
Sep 23, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion